Corvus Pharmaceuticals, Inc.
CRVS- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001626971
No open-market purchases or sales by Corvus Pharmaceuticals, Inc. insiders were filed in the last 90 days; 173 institutions reported holding it in 13F filings for Q2 2026, worth $1.06B in total; no superinvestor holds it.
13F holders, Q2 2025
Institutional positions in Corvus Pharmaceuticals, Inc. as of Jun 30, 2025. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 92
- +4 vs. Q1 2025
- Shares held
- 41.8M
- +5.49M (+15.1%) vs. Q1 2025
- Total value
- $167.1M
- +$51.7M (+44.8%) vs. Q1 2025
- New holders
- 33
- 32 more added
- Sold out
- 29
- 10 more reduced
Compare with Q1 2025: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting CRVS on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 173 | $1.06B |
| Q1 2026 | 164 | $1.02B |
| Q4 2025 | 124 | $359.4M |
| Q3 2025 | 103 | $312.7M |
| Q2 2025 | 92 | $167.1M |
| Q1 2025 | 88 | $115.4M |
| Q4 2024 | 86 | $202.0M |
| Q3 2024 | 62 | $158.5M |
| Q2 2024 | 47 | $50.2M |
| Q1 2024 | 47 | $31.9M |
| Q4 2023 | 48 | $33.8M |
| Q3 2023 | 52 | $28.0M |
| Q2 2023 | 52 | $44.6M |
| Q1 2023 | 37 | $18.9M |
| Q4 2022 | 42 | $18.2M |
| Q3 2022 | 48 | $18.1M |
| Q2 2022 | 47 | $25.4M |
| Q1 2022 | 57 | $44.9M |
| Q4 2021 | 62 | $66.7M |
| Q3 2021 | 61 | $136.4M |
| Q2 2021 | 50 | $63.2M |
| Q1 2021 | 49 | $62.8M |
Institutions, Q2 2025
Shares, value and share of portfolio for each institution holding Corvus Pharmaceuticals, Inc.; share changes are against Q1 2025.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Balyasny Asset Management LLC | 0 | $0 | 0.00% | −57,827−100.0% | Sold out |
| EntryPoint Capital, LLC | 0 | $0 | 0.00% | −53,745−100.0% | Sold out |
| Jain Global LLC | 0 | $0 | 0.00% | −48,145−100.0% | Sold out |
| Jump Financial, LLC | 0 | $0 | 0.00% | −45,013−100.0% | Sold out |
| Schonfeld Strategic Advisors LLC | 0 | $0 | 0.00% | −39,783−100.0% | Sold out |
| Quantessence Capital LLC | 0 | $0 | 0.00% | −36,421−100.0% | Sold out |
| Cannon Global Investment Management, LLC | 0 | $0 | 0.00% | −35,000−100.0% | Sold out |
| LMR Partners LLP | 0 | $0 | 0.00% | −29,858−100.0% | Sold out |
| Simplex Trading, LLC | 0 | $0 | 0.00% | −26,990−100.0% | Sold out |
| Verition Fund Management LLC | 0 | $0 | 0.00% | −24,413−100.0% | Sold out |
| Dimensional Fund Advisors LP | 0 | $0 | 0.00% | −22,793−100.0% | Sold out |
| Oppenheimer & Co Inc | 0 | $0 | 0.00% | −22,534−100.0% | Sold out |
| Quinn Opportunity Partners LLC | 0 | $0 | 0.00% | −22,327−100.0% | Sold out |
| Brevan Howard Capital Management LP | 0 | $0 | 0.00% | −21,738−100.0% | Sold out |
| UBS Oconnor LLC | 0 | $0 | 0.00% | −20,850−100.0% | Sold out |
| Leonteq Securities AG | 0 | $0 | 0.00% | −20,000−100.0% | Sold out |
| XTX Topco Ltd | 0 | $0 | 0.00% | −14,958−100.0% | Sold out |
| Capula Management Ltd | 0 | $0 | 0.00% | −14,793−100.0% | Sold out |
| Capstone Investment Advisors, LLC | 0 | $0 | 0.00% | −12,644−100.0% | Sold out |
| Group One Trading, L.P. | 0 | $0 | 0.00% | −11,895−100.0% | Sold out |
| Prelude Capital Management, LLC | 0 | $0 | 0.00% | −10,027−100.0% | Sold out |